[HTML][HTML] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
[引用][C] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
A Daly, A Rettie, D Fowler, J Miners - Journal of Personalized Medicine, 2017 - cir.nii.ac.jp
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
AK Daly, AE Rettie, DM Fowler… - Journal of Personalized …, 2018 - eprints.ncl.ac.uk
Abstract© 2018 by the authors. Licensee MDPI, Basel, Switzerland. CYP2C9 is the most
abundant CYP2C subfamily enzyme in human liver and the most important contributor from …
abundant CYP2C subfamily enzyme in human liver and the most important contributor from …
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
AK Daly, AE Rettie, DM Fowler… - Journal of Personalized …, 2018 - search.ebscohost.com
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
[PDF][PDF] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
AK Daly, AE Rettie, DM Fowler, JO Miners - pdfs.semanticscholar.org
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
[HTML][HTML] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
AK Daly, AE Rettie, DM Fowler… - Journal of Personalized …, 2018 - ncbi.nlm.nih.gov
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
A Daly, A Rettie, D Fowler… - Journal of …, 2018 - researchnow.flinders.edu.au
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
[PDF][PDF] Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
AK Daly, AE Rettie, DM Fowler, JO Miners - e-helvetica.nb.admin.ch
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
AK Daly, AE Rettie, DM Fowler… - Journal of Personalized …, 2017 - europepmc.org
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
AK Daly, AE Rettie, DM Fowler… - Journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …